Company Performance Metrics
Oxilio is a pharmaceutical company that develops repurposed and reformulated drug candidates focused on oncology therapeutics. The company identifies existing, historically approved drugs and redesigns them for new cancer indications, aiming to address unmet needs in cancer treatment. Its approach centers on avoiding early-stage discovery by
working with known clinical molecules and applying rigorous modeling and simulation to guide development. Oxilio advances oral drug formulations and other dosage forms to improve bioavailability, patient compliance, and treatment experience. The pipeline includes candidates such as OXL001 and OXL002, which are based on off-patent drugs previously approved for different indications and are reformulated for multiple cancer types. The company also develops intellectual property around novel formulations and delivery strategies in oncology and related therapeutic areas.
